This paper appraises the Human Papillomavirus Vaccine as new health technology that should be funded by the Australian ministry of health. It gives a vivid description of the randomized double-blind placebo-controlled study to ascertain the effectiveness of the vaccine in reducing cervical cancer infection among young women. The paper also gives an economic evaluation of the cost-effectiveness of adding the HPV vaccine to the national cervical cancer screening program. The cost per LY is projected to be $92 052 and the cost per QALY is $33 644 evidence in both boys and girls. The nature of clinical evidence for safety, effectiveness, and efficacy of the HPV vaccine are also evaluated for a conclusive discussion. The paper concludes by assessing the applicability of the HPV vaccine in the Australian context giving the possible implication on the budget. The paper provides a recommendation that the vaccine should be funded as it proves cost reduction due to reduced cost of treatment for cervical cancer.
![[object Object]](/_next/image/?url=%2F_next%2Fstatic%2Fmedia%2Flogo.6d15ce61.png&w=640&q=75){kind=small}
![[object Object]](/_next/static/media/star-bottom.7253800d.svg)
